|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400085870 |
|
最近更新日期: Date of Last Refreshed on: |
2024-06-20 09:25:36 |
|
注册时间: Date of Registration: |
2024-06-20 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
围手术期康复治疗促进前列腺钬激光剜除术后尿控恢复的随机对照单中心临床试验 |
|
Public title: |
A randomized controlled single-center clinical trial of perioperative rehabilitation to promote recovery of urinary continence after holmium laser enucleation of the prostate |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
围手术期康复治疗促进前列腺钬激光剜除术后尿控恢复的随机对照单中心临床试验 |
|
Scientific title: |
A randomized controlled single-center clinical trial of perioperative rehabilitation to promote recovery of urinary continence after holmium laser enucleation of the prostate |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陆晓俊 |
研究负责人: |
周铁;张安仁 |
|
Applicant: |
Xiaojun Lu |
Study leader: |
Tie Zhou; AnRen Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 185 2135 8926 |
研究负责人电话: Study leader's telephone: |
+86 139 1836 0532 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
460532253@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
wenzhoutie@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市三门路1279号 |
研究负责人通讯地址: |
上海市三门路1279号 |
|
Applicant address: |
No. 1279 Sanmen Road, Shanghai |
Study leader's address: |
No. 1279 Sanmen Road, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
200434 |
研究负责人邮政编码: Study leader's postcode: |
200434 |
|
申请人所在单位: |
同济大学附属上海市第四人民医院 |
||
|
Applicant's institution: |
Shanghai Fourth People's Hospital, Affiliated to Tongji University |
||
|
研究负责人所在单位: |
同济大学附属上海市第四人民医院 |
||
|
Affiliation of the Leader: |
Shanghai Fourth People's Hospital, Affiliated to Tongji University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024062-001 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市第四人民医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Shanghai Fourth People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-03-28 00:00:00 |
||
|
伦理委员会联系人: |
张其胜 |
||
|
Contact Name of the ethic committee: |
Qisheng Zhang |
||
|
伦理委员会联系地址: |
上海市三门路1279号同济大学附属上海市第四人民医院A727室 |
||
|
Contact Address of the ethic committee: |
Room A727, Shanghai Fourth People's Hospital, Affiliated to Tongji University, No. 1279 Sanmen Road, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 55603999 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
同济大学附属上海市第四人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Fourth People's Hospital, Affiliated to Tongji University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市三门路1279号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 1279 Sanmen Road, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海市第四人民医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shanghai Fourth People's Hospital |
||||||||||||||||||||||
|
Target disease: |
Urinary incontinence after prostate enucleation |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
研究围手术期康复治疗促进前列腺钬激光剜除术后尿控恢复的临床疗效 |
||||||||||||||||||||||
|
Objectives of Study: |
To study the clinical efficacy of perioperative rehabilitation therapy in promoting the recovery of urinary continence after holmium laser enlation of the prostate |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)年龄≥50周岁男性; (2)前列腺增生反复血尿、反复尿路感染、近期急性尿潴留、合并膀胱结石、肾功能损害或药物治疗效果不佳,愿意接受Holep手术; (3)同意在本试验过程中完成排尿日记(备选),尿垫试验等检查项目 ; (4)血清前列腺特异性抗原(PSA)< 4ng/mL,或PSA> 4ng/mL,但前列腺穿刺确诊为良性前列腺组织。 (5)前列腺超声检查提示患者前列腺体积(PV)≥30cm3。 (6)导入期前1周内未接受过针灸、生物电反馈等治疗; (7)理解参加研究的风险和受益,自愿受试,能够签署知情同意书; |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Male ≥ age 50 years old; (2) Prostatic hyperplasia, recurrent hematuria, recurrent urinary tract infection, recent acute urinary retention, bladder stones, renal impairment or poor drug treatment effect, willing to undergo Holep surgery; (3) Agree to complete the urination diary (optional), urine pad test and other examination items during the test; (4) Serum prostate-specific antigen (PSA) < 4ng/mL, or PSA > 4ng/mL, but prostate puncture confirms benign prostate tissue. (5) Prostate ultrasound showed that the patient's prostate volume (PV) was ≥ 30cm3. (6) Have not received acupuncture, bioelectric feedback and other treatments within 1 week before the introduction period; (7) Understand the risks and benefits of participating in the study, voluntarily take the test, and be able to sign the informed consent form; |
||||||||||||||||||||||
|
排除标准: |
(1)有老年痴呆、脑梗或毒品或者酒精造成认知功能障碍患者; (2)既往有脊柱裂、脊髓损伤、脊柱手术、脑梗脑出血等疾病造成膀胱功能障碍; (3)过去6个月内发生心肌梗死、心绞痛、脑血管意外、心力衰竭; (4)合并血液系统疾病、消化道出血、糖尿病周围神经病变; (5)过去1年正从癌症中康复,或接受过骨盆区域放疗术后,或既往盆腔、下腹部手术或创伤史; (6)合并有神经精神心理疾患及无法合作或不愿合作者; (7)近3月服用索利那新、托特罗定、溴吡斯的明等影响膀胱功能的药物; (8)尿动力学检查提示神经源性膀胱、储尿期逼尿肌不稳定收缩、逼尿肌括约肌协同失调、逼尿肌收缩乏力等明确影响手术效果的情况; (9)尿道狭窄、前列腺癌、留置尿管病人,下肢静脉超声提示静脉血栓病人。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Patients with Alzheimer's disease, cerebral infarction, or cognitive dysfunction caused by drugs or alcohol; (2) Bladder dysfunction caused by previous diseases such as spina bifida, spinal cord injury, spinal surgery, cerebral infarction and cerebral hemorrhage; (3) Myocardial infarction, angina, cerebrovascular accident, and heart failure within the past 6 months; (4) Combined with hematologic diseases, gastrointestinal bleeding, diabetic peripheral neuropathy; (5) Recovering from cancer in the past 1 year, or having undergone radiotherapy in the pelvic region, or previous pelvic or lower abdominal surgery or trauma history; (6) Those with neuropsychiatric disorders and those who are unable or unwilling to cooperate; (7) Taking drugs affecting bladder function such as solifenacin, tolterodine, and pyridostigmine bromide in the past 3 months; (8) Urodynamic examination showed neurogenic bladder, unstable contraction of detrusor during the storage period, dyscoordination of detrusor sphincter, and weakness of detrusor contraction, which clearly affected the effect of surgery; (9) Patients with urethral stenosis, prostate cancer, indwelling urethral catheter, and venous thrombosis on venous ultrasound of lower limbs. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-07-01 00:00:00至 To 2025-07-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-07-01 00:00:00 至 To 2025-07-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男性 |
Gender: |
Male |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
应用SPSS软件的随机数字生成器和Group函数随机分组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The random number generator and Group function of SPSS software were used to randomly group groups |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无盲法 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |